Metronidazole

"Metronidazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed).

Descriptor ID	D008795
MeSH Number(s)	D02.640.672.500 D03.383.129.308.658.500
Concept/Terms	Metronidazole Metronidazole 2-Methyl-5-nitroimidazole-1-ethanol 2 Methyl 5 nitroimidazole 1 ethanol Trichazol Trichazol Trichopol Trichopol Trivazol Trivazol Vagilen Vagilen Bayer 5360 Bayer 5360 Clont Clont Danizol Danizol Flagyl Flagyl Gineflavir Gineflavir Metric Metric Metrodzhil Metrodzhil MetroGel MetroGel Metrogyl Metrogyl Metronidazole Hydrochloride Metronidazole Hydrochloride Hydrochloride, Metronidazole Metronidazole Monohydrochloride Monohydrochloride, Metronidazole Metronidazole Phosphate Metronidazole Phosphate Phosphate, Metronidazole Metronidazole Phosphoester Phosphoester, Metronidazole Satric Satric

Below are MeSH descriptors whose meaning is more general than "Metronidazole".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Nitro Compounds [D02.640]
Nitroimidazoles [D02.640.672]
Metronidazole [D02.640.672.500]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Nitroimidazoles [D03.383.129.308.658]
Metronidazole [D03.383.129.308.658.500]

Below are MeSH descriptors whose meaning is related to "Metronidazole".

Below are MeSH descriptors whose meaning is more specific than "Metronidazole".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Metronidazole" by people in this website by year, and whether "Metronidazole" was a major or minor topic of these publications.

Bar chart showing 35 publications over 18 distinct years, with a maximum of 7 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2002	0	1	1
2004	1	0	1
2005	2	0	2
2006	3	0	3
2007	2	0	2
2008	1	0	1
2010	1	0	1
2011	0	1	1
2013	0	2	2
2014	1	2	3
2015	6	1	7
2016	0	1	1
2017	2	2	4
2018	1	0	1
2019	2	0	2
2021	0	1	1
2023	0	1	1

Below are the most recent publications written about "Metronidazole" by people in Profiles.

Klebanoff MA, Schuit E, Lamont RF, Larsson PG, Odendaal HJ, Ugwumadu A, Kiss H, Petricevic L, Andrews WW, Hoffman MK, Shennan A, Seed PT, Goldenberg RL, Emel LM, Bhandaru V, Weiner S, Larsen MD. Antibiotic treatment of bacterial vaginosis to prevent preterm delivery: Systematic review and individual participant data meta-analysis. Paediatr Perinat Epidemiol. 2023 03; 37(3):239-251.

View in: PubMed
Muzny CA, Schwebke JR, Nyirjesy P, Kaufman G, Mena LA, Lazenby GB, Van Gerwen OT, Graves KJ, Arbuckle J, Carter BA, McMahon CP, Eder S, Shaw J, Pandey B, Chavoustie SE. Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study. Clin Infect Dis. 2021 09 15; 73(6):e1282-e1289.

View in: PubMed
Shafquat Y, Jabeen K, Farooqi J, Mehmood K, Irfan S, Hasan R, Zafar A. Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan. Antimicrob Resist Infect Control. 2019; 8:99.

View in: PubMed
Henien M, Nyirjesy P, Smith K. Metronidazole-Resistant Trichomoniasis: Beneficial Pharmacodynamic Relationship With High-Dose Oral Tinidazole and Vaginal Paromomycin Combination Therapy. Sex Transm Dis. 2019 01; 46(1):e1-e2.

View in: PubMed
Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018 04; 13:507-524.

View in: PubMed
Stemmer SM, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Trichomonas vaginalis is most frequently detected in?women at the age of peri-/premenopause: an unusual pattern for a sexually transmitted pathogen. Am J Obstet Gynecol. 2018 03; 218(3):328.e1-328.e13.

View in: PubMed
Schwebke JR, Morgan FG, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017 12; 217(6):678.e1-678.e9.

View in: PubMed
Hillier SL, Nyirjesy P, Waldbaum AS, Schwebke JR, Morgan FG, Adetoro NA, Braun CJ. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2017 08; 130(2):379-386.

View in: PubMed
Webster G, Schaller M, Tan J, Jackson JM, Kerrouche N, Sch?fer G. Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis. J Dermatolog Treat. 2017 Aug; 28(5):469-474.

View in: PubMed
Minneci PC, Mahida JB, Lodwick DL, Sulkowski JP, Nacion KM, Cooper JN, Ambeba EJ, Moss RL, Deans KJ. Effectiveness of Patient Choice in Nonoperative vs Surgical Management of Pediatric Uncomplicated Acute Appendicitis. JAMA Surg. 2016 05 01; 151(5):408-15.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement